FiercePharma

Exenatide Once Monthly Showed Positive Results in Phase 2 Study

The 121-patient, phase 2 study assessed the efficacy, safety and tolerability of three different doses of exenatide once monthly. It also assessed exenatide once weekly (exenatide extended-release for ...
Daily Sundial

Bydureon Weight Loss Injection Review – Bydureon Bcise Exenatide Extended Release Alternatives Over the Counter

Below are 3 natural substitutes to Bydureon that can reduce body weight and control blood sugar levels. For best results it is possible to use in a stack – this means combining 2 or more products ...
Healio

Once-weekly exenatide improved glucose control, weight loss in DURATION studies

Please provide your email address to receive an email when new articles are posted on . ORLANDO — A once-weekly injection of exenatide may be an important therapeutic option for patients with type 2 ...
FierceBiotech

PRESS RELEASE: Once-Weekly Exenatide Showed Statistical Superiority in Glucose Control Compared to BYETTA in Head-to-Head Study

SAN DIEGO & INDIANAPOLIS & CAMBRIDGE, Mass., Oct 31, 2007 (BUSINESS WIRE) -- Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN), Eli Lilly and Company (NYSE: LLY) and Alkermes, Inc. (NASDAQ: ALKS) today ...
Healio

Exenatide reduced HF risk by half in type 2 diabetes

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio Data from a retrospective analysis have ...
FiercePharma

U.S. FDA Approves Bydureon® Pen (exenatide extended-release for injectable suspension) for Once-Weekly Treatment of Adults with Type 2 Diabetes

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca (NYSE:AZN) today announced that the U.S. Food and Drug Administration (FDA) has approved the Bydureon® Pen (exenatide extended-release for injectable ...
Benzinga.com

EXCLUSIVE: Vivani Medical Announces First Implant In Early-Stage Human Study Of GLP-1 Implant For Obesity

On Thursday, Vivani Medical, Inc. (NASDAQ:VANI) announced the administration of its first GLP-1 (exenatide, NPM-115) implant in the LIBERATE-1 trial in Australia. Vivani's lead program, NPM-115, ...
Medscape

The Role of Adjunctive Exenatide Therapy in Pediatric Type 1 Diabetes

Our study demonstrates reduction in postprandial glucose after exenatide injection in adolescents with type 1 diabetes. These effects were associated with delayed gastric emptying, and the results are ...
Business Wire

Vivani Medical Announces Positive Preclinical Liver Fat Results with Miniature, Ultra Long-Acting GLP-1 Implant

Vivani’s GLP-1 (exenatide) implant produced sham-implant adjusted liver fat reduction of 82% in an obese mouse model from a single administration with expected twice-yearly dosing Vivani previously ...
Nasdaq

Once-weekly Trulicity® (dulaglutide) demonstrates significantly higher adherence and more persistence compared to once-weekly semaglutide and exenatide injections

TORONTO, June 19, 2020 (GLOBE NEWSWIRE) -- New real-world data showed Trulicity® (dulaglutide) had significantly higher adherence and longer persistence compared to weekly injections of semaglutide or ...
FierceBiotech

Exenatide Once Monthly Showed Positive Results in Phase 2 Study

SAN DIEGO & INDIANAPOLIS & WALTHAM, Mass.--(BUSINESS WIRE)-- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), Eli Lilly and Company (NYSE: LLY) and Alkermes, Inc. (Nasdaq: ALKS) today announced positive ...